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ORIGINAL ARTICLE
AKT overactivation can suppress DNA repair via p70S6
kinase-dependent downregulation of MRE11
D Piscitello1, D Varshney2, S Lilla1, MG Vizioli3, C Reid3, V Gorbunova4, A Seluanov4, DA Gillespie5 and PD Adams3
Deregulated AKT kinase activity due to PTEN deﬁciency in cancer cells contributes to oncogenesis by incompletely understood
mechanisms. Here, we show that PTEN deletion in HCT116 and DLD1 colon carcinoma cells leads to suppression of CHK1 and CHK2
activation in response to irradiation, impaired G2 checkpoint proﬁciency and radiosensitization. These defects are associated with
reduced expression of MRE11, RAD50 and NBS1, components of the apical MRE11/RAD50/NBS1 (MRN) DNA damage response
complex. Consistent with reduced MRN complex function, PTEN-deﬁcient cells fail to resect DNA double-strand breaks efﬁciently
after irradiation and show greatly diminished proﬁciency for DNA repair via the error-free homologous recombination (HR) repair
pathway. MRE11 is highly unstable in PTEN-deﬁcient cells but stability can be signiﬁcantly restored by inhibiting mTORC1 or p70S6
kinase (p70S6K), downstream kinases whose activities are stimulated by AKT, or by mutating a residue in MRE11 that we show is
phosphorylated by p70S6K in vitro. In primary human ﬁbroblasts, activated AKT suppresses MRN complex expression to escalate
RAS-induced DNA damage and thereby reinforce oncogene-induced senescence. Taken together, our data demonstrate that
deregulation of the PI3K-AKT/ mTORC1/ p70S6K pathways, an event frequently observed in cancer, exert profound effects on
genome stability via MRE11 with potential implications for tumour initiation and therapy.
Oncogene advance online publication, 2 October 2017; doi:10.1038/onc.2017.340
INTRODUCTION
Phosphatase and tensin homologue deleted on chromosome 10
(PTEN) is a tumour suppressor gene found altered in multiple
sporadic tumours.1,2 Lesions in the PTEN gene occur at almost the
same frequency as TP53 alterations in certain tumour types.3 Its
chief function is to antagonize phosphatidylinositol 3-kinase (PI3K)
signalling, so that impaired PTEN function leads to unrestrained
activation of its downstream signals and results in high levels of
constitutively active AKT.4 AKT is key node on the PI3K pathway
and controls the activation of the major signalling pathways for
cell growth, survival and metabolism by phosphorylating many
downstream signalling targets.5 The ampliﬁcation of PIK3CA (the
gene encoding for the p110α catalytic subunit of PI3K) also causes
growth factor-independent constitutive activation of AKT, and is
often found in ovarian and cervical cancers.6–8 mTOR complex 1
(mTORC1) is a well known effector of activated AKT. AKT signals
through direct phosphorylation of the TSC1/TSC2 complex to
indirectly activate mTORC1.9,10 A crucial effector of mTORC1 is 40S
ribosomal protein S6 kinase (S6K).11 S6K directly regulates
ribosome biogenesis, cell cycle progression, protein synthesis and
metabolism.12,13
The centrality of the genome to cell function, phenotype and
viability means that challenges to genome stability and acquisi-
tion of genome instability have profound consequences for the
cell. For example, primary non-transformed cells can undergo
senescence if they incur irreparable DNA damage. Senescence is
an irreversible growth arrest associated with morphological and
gene expression changes.14,15 Expression of the oncogenic form of
RAS (HRASG12V) can lead to oncogene-induced senescence (OIS)
due to accumulation of unrepaired damaged DNA caused by
unscheduled DNA synthesis.16,17 DNA damage-activated OIS poses
a potent barrier to tumourigenesis,14,15 and cells that escape or
bypass OIS are at risk of progression to cancer.
In contrast to primary non-transformed cells, cancer cells often
possess an unstable genome that leads to gross genetic
alterations, clonal evolution and tumour heterogeneity.18,19 The
cellular DNA damage response (DDR) has a crucial role in the
maintenance of genomic stability. Mutations in the DDR pathway
allow the survival and proliferation of cells with genomic
abnormalities, promoting oncogenic transformation and therefore
tumourigenesis. However, inherent defects in DNA repair pro-
cesses also provide an important therapeutic opportunity. For
instance, tumours deﬁcient for BRCA1/2 genes are highly sensitive
to interstrand DNA crosslinking agents, such as cisplatin and
carboplatin, and to a new class of anti-cancer agents called poly
(ADP-ribose) polymerase (PARP) inhibitors.20–22
Inactivation of PTEN has been linked to genome instability in
cancer. For example, an early report showed that lack of PTEN
initiates genome instability through mislocalization of CHK1.23
Another report showed that PTEN confers centromeric stability
and suppression of DNA double-strand breaks, in part though
control of RAD51 function.24 Potentially contributing to genome
instability in PTEN-deﬁcient cells, several lines of evidence have
shown that the PI3K/PTEN/AKT pathway has a role in modulating
cell-cycle checkpoint activation and DNA repair. High levels of AKT
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can inhibit homologous recombination (HR) repair by suppressing
the formation of BRCA1 and Rad51 foci, speciﬁcally after exposure
to Irradiation (IR) in breast cancer.25 Overactivated AKT or PTEN
loss can also overcome the DNA damage-induced G2 cell cycle
checkpoint and Chk1 activation upon exposure to genotoxic
stresses.23,26–29 Thus, neoplastic cells expressing constitutively
active AKT can avoid apoptosis and checkpoint-dependent cell
cycle arrest, and accumulate potential cancer-causing mutations
due to suppression of HR and reliance on error-prone NHEJ.
Given the potent suppressor activity of PTEN, we set out to
discover additional mechanisms by which inactivation of PTEN
promotes genome instability. We show that increased AKT-mTOR-
S6K activity upon loss of PTEN leads to phosphorylation and
degradation of MRE11 nuclease and impairs the DNA damage
response in colorectal carcinoma cells. However, in non-
transformed primary ﬁbroblasts, elevated AKT activity, suppression
of DNA repair and accumulation of DNA damage lead to a
consolidation of RAS-induced senescence. Therefore, we propose
a new mechanism by which loss of PTEN and consequent
activation of the PI3K-AKT-mTORC1-S6K1 signalling pathway
impairs DNA repair by downregulation of MRE11. In primary cells,
this accumulated DNA damage can reinforce tumour suppression,
but in cancer cells can promote genome instability.
RESULTS
PTEN deﬁciency suppresses DNA damage signalling via MRN
complex hypomorphism
To investigate the impact of PTEN deﬁciency on DNA damage
signalling, we ﬁrst compared irradiation-induced activation of
CHK1 and CHK2 in HCT116 colon carcinoma cells and an isogenic
sister cell line in which PTEN was ablated by gene targeting. As
expected, HCT116 PTEN− /− cells exhibit very high basal levels of
active AKT phosphorylated at serine 473 (S473) compared with the
parental HCT116 cell line owing to the absence of PTEN
expression (Figure 1a, left). Western blot analysis 1 h post
irradiation revealed that activation of CHK1 (phosphorylated at
S345) and CHK2 (phosphorylated at T68) was signiﬁcantly
impaired in HCT116 PTEN− /− cells compared with the control.
Importantly, diminished activation of CHK1 and CHK2 was also
observed in isogenically matched DLD1 and DLD1 PTEN− /− cells,
indicating that this phenomenon is not conﬁned to HCT116
(Figure 1a, right).
The MRE11/RAD50/NBS1 (MRN) complex is a key regulator of
DNA damage signalling that is required both for optimal
activation of ATM, the upstream regulator of CHK2, and for
activation of ATR, the upstream regulator of CHK1. Remarkably, we
found that the basal expression level of both MRE11 and its
partner protein RAD50 were signiﬁcantly diminished in HCT116
PTEN− /− cells compared with the control (Figure 1a, left). Previous
publications have suggested that HCT116 cells contain MRE11
mRNA-lacking exons 5–7, causing expression of a truncated non-
functional protein.30 However, RT–PCR on cDNA from our HCT116
WT and PTEN− /− cells did not reveal the presence of the mutated
cDNA (Supplementary Figure 1A). In addition, we only detect the
full-length protein in our western blot assays. In agreement with
the HCT116, a similar decrease in the basal expression of MRE11
was observed in DLD1 PTEN− /− cells (Figure 1a, right). However,
RAD50 was not as markedly reduced as in HCT116 PTEN− /− cells,
suggesting that additional factors govern stability of these two
proteins. We then investigated the effect of siRNA-mediated
depletion of MRE11 on DNA damage signalling. Reduced MRE11
expression impaired activation of both CHK1 and CHK2, indicating
that the lower level seen in PTEN− /− cells is indeed limiting for
optimal DNA damage signalling (Figure 1b). We also pre-treated
wild-type HCT116 cells with Mirin, a small molecule inhibitor of
MRE11 catalytic activity, and found that 100 μM Mirin also
impaired activation of CHK1 and CHK2 after irradiation
(Figure 1c). Taken together, these observations indicate that
diminished levels of MRN contribute to the attenuation of CHK1
and CHK2 activation in PTEN-deﬁcient cells after irradiation.
Checkpoint proﬁciency and DNA repair is attenuated in the
absence of PTEN
Activation of CHK1 and CHK2 is required for cell cycle arrest in G2
in response to DNA damage. Therefore, we investigated whether
this checkpoint was altered in the absence of PTEN. To this end,
we treated HCT116 and HCT116 PTEN− /− cells with nocodazole for
9 h, with or without prior irradiation at increasing doses, and
performed cell cycle analysis by ﬂuorescence-activated cell sorting
(FACS) of cells stained with propidium iodide and an antibody to
histone H3 phosphorylated at serine 10 (the latter a marker of
mitosis). This analysis revealed that the mitotic index, that is,
percentage of cells in M-phase, was considerably higher in
HCT116 PTEN− /− cells compared with wild-type at all doses
tested, indicating that fewer cells succeeded in arresting in G2
after irradiation-induced damage (Figure 2a).
Cell cycle arrest in G2 is thought to provide cells with an
opportunity to repair DNA damage, particularly using the error-
free mechanism of HR. As MRN has a key role in initiating HR by
promoting the formation of single-stranded DNA (ssDNA) by
strand resection, we considered that this process might be
attenuated in the absence of PTEN function. The loss of PTEN does
not lead to alterations in the cell cycle proﬁle of HCT116 cells
(Supplementary Figure 1B). We therefore compared the amount
and distribution of ssDNA formed in wild-type and HCT116
PTEN− /− cells after irradiation using replication protein A (RPA)
focus formation as a surrogate marker. HCT116 PTEN− /− cells
show marked reduction in RPA foci compared with wild-type,
indicating a failure to form ssDNA efﬁciently (Figure 2b). In
addition, a similar effect was observed in parental HCT116 cells
pre-treated with 100 μM Mirin prior to irradiation, arguing that the
formation of ssDNA/RPA foci also depends on MRE11 catalytic
activity (Figure 2b).
To measure proﬁciency for DNA repair directly, we transfected
HCT116 wild-type and PTEN− /− cells with plasmids containing
modiﬁed green ﬂuorescent protein (GFP) coding sequences that
permit the efﬁciency of repair mediated by HR or non-
homologous end-joining (NHEJ) to be measured directly by ﬂow
cytometry as described previously.31 Remarkably, this analysis
revealed that DNA repair mediated by HR was much less efﬁcient
in HCT116 PTEN− /− cells compared with control, whereas
proﬁciency for NHEJ was increased (Figure 2c). Importantly, the
efﬁciency of HR in parental HCT116 cells could be reduced both by
prior siRNA-mediated depletion of MRE11 or pre-treatment with
Mirin, indicating that a normal basal level of MRE11 expression
and catalytic activity are necessary for optimal HR under these
conditions.
Defects in DNA repair frequently confer increased sensitivity to
radiation and other DNA damaging agents. Consistent with the
observed deﬁcit in HR capacity, HCT116 PTEN− /− cells were very
much more sensitive to radiation than wild-type parental cells
over a wide range of doses when tested in a clonogenic survival
assay (Figure 2d). Clonogenic cell survival was also compromised
when cells were treated with Mirin during the irradiation and
recovery period, although the scale of this effect was less than the
difference between parental and HCT116 cells HCT116 PTEN− /−
(Figure 2d).
MRE11 is rapidly degraded in PTEN-deﬁcient cells
The diminished levels of MRN components seen in HCT116
PTEN− /− cells compared with parental HCT116 could result from
decreased transcription of genes encoding these proteins, more
rapid protein degradation, or a combination of both. RT–qPCR
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analysis revealed no signiﬁcant difference in the levels of mRNAs
encoding MRE11, RAD50 and NBS1/p95. However, as expected,
PTEN mRNA was essentially undetectable in the genetically
engineered PTEN knockout line (Figure 3a). To evaluate protein
stability, we treated HCT116 and HCT116 PTEN− /− cells with
cycloheximide for 7 and 24 h. MRE11, RAD50 and NBS1/p95 were
degraded more rapidly in HCT116 PTEN− /− cells compared with
parental HCT116 (Figure 3b). In striking contrast, p53 was equally
labile in both cell types.
We also examined the stability of exogenous MRE11 transfected
into parental and PTEN-deﬁcient HCT116 cells. Cells transfected
with a vector encoding Myc-Flag-tagged human MRE11 for 32 or
48 h, were treated with cycloheximide or vehicle for a further 8 or
24 h, respectively. This analysis demonstrated that exogenous
MRE11 did not accumulate to the same level in HCT116 PTEN− /−
as parental HCT116 cells (Figure 3c). Consistent with this, when the
cells were challenged with cycloheximide, we observed that the
exogenous, tagged MRE11 protein was degraded more rapidly in
PTEN-deﬁcient than parental HCT116 cells. As before, p53 was
equally labile in both cell types (Figure 3c).
mTORC1 and p70S6 kinase signalling promotes MRE11 degradation
Inactivation of PTEN elevates the AKT activity (Figure 1a). To
determine whether MRE11 stability could be diminished by
increasing the basal level of AKT activity in parental HCT116 cells,
we overexpressed GAG-AKT, a constitutively active form that is
resistant to inhibition by PTEN. This augmented the overall level of
active, S473-phosphorylated AKT two- to threefold after 24 h
Figure 1. PTEN deﬁciency suppresses DNA damage signalling via MRN complex hypomorphism. (a) Western blots of indicated proteins were
performed on whole-cell extracts from HCT116 and DLD1 (WT or PTEN− /−) cells 1h post irradiation with 10 Gy. Actin provides the loading
control. (b) Western blot analysis was performed on whole-cell extracts from HCT116 WT cells 48 h post transfection with 200 nM smart pool
siRNA against MRE11 or non-targeting siRNA pool and 1 h post irradiation with 10 Gy. Actin provides the loading control. (c) Western blot
analysis was performed on whole-cell extracts from HCT116 WT cells, generated 1 h after exposure to 10 Gy irradiation and pre-treatment with
50 and 100 μM Mirin for 40 min. Actin provides the loading control.
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Figure 2. Checkpoint proﬁciency and DNA repair is attenuated in the absence of PTEN. (a) FACS analysis measuring phopho-histone H3 levels
and PI incorporation in replicate cultures of HCT116 WT and PTEN− /− cells with or without prior exposure to different doses of IR and
incubation with nocodazole for 9 h. FACS data present the mitotic index (ratio of cells in M-phase positive for phosphorylated H3 over total
number of cells × 100). The data are normalized to the nocodazole (noc) sample not exposed to IR and average± S.D. of n= 3 are plotted.
(b) Immunoﬂuorescence analysis of phosphorylated H2Ax (γ-H2AX) and RPA foci in HCT116 WT with or without pre-treatment with Mirin, and
in PTEN− /− cells 4 h after exposure to 10 Gy IR. Quantiﬁcation of the number of RPA foci per nuclei. Error bars show S.D. for three independent
biological replicates. (c) Frequency of NHEJ and HR was analysed with two independent NHEJ and HR constructs in HCT116 WT and PTEN− /−
cell lines. The WT cell line was either pre-transfected with control siRNA or siRNA pool against MRE11 or pre-treated with 15 μM Mirin 40 min
prior to transfection with linearized constructs. The ratio of GFP+/DsRed+ cells was used to measure repair efﬁciency and is presented as a
percentage of the untreated WT control. Error bars show s.e.m. for three independent biological replicates. ** denote Po0.01 as calculated by
Student’s t-test. (d) Survival curves plotted with the number of colonies determined by the GelCount (Oxford Optronix, Abingdon, UK). %
Survival was calculated relative to the cells untreated with IR. Error bars show s.d. for three independent biological replicates.
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(Figure 4a). Importantly, after 48 and 72 h of elevated AKT activity,
there was a several fold decrease in the basal levels of MRE11 and
RAD50, indicating that expression of a constitutively active form of
AKT can mimic the effect of PTEN deletion.
We next asked whether the converse manipulations, namely
chemical inhibition of AKT, or the downstream kinases mTORC1
and p70S6K, could rescue the diminished level of MRE11 and
impaired DNA damage signalling seen in PTEN-deﬁcient cells. To
this end, we treated HCT116 PTEN− /− cells with inhibitors of AKT
(AKT1/2i), mTORC1 (Everolimus) or p70S6K (S6K1i) for 72 h and
then evaluated the expression levels of MRE11, and activation of
CHK1 and CHK2 either with or without irradiation.
Surprisingly, inhibition of AKT alone had little or no effect on
MRE11 and RAD50 levels or CHK2 activation after irradiation,
Figure 3. MRE11 is rapidly degraded in PTEN-deﬁcient HCT116 cells. (a) RT–qPCR analysis of MRE11, RAD50 and NBS1 mRNAs in HCT116 WT
and PTEN− /− cells. Data were normalized to ACTIN mRNA and are presented relative to the WT signal. The error bars represent the s.d. of three
independent biological replicates. (b) Western blot analysis of HCT116 WT and PTEN− /− cells following treatment with cycloheximide for 7 and
24 h. p53 provides the positive control and actin provides the loading control. The graph represents the quantiﬁcation of the MRE11 western
blot analysis using ImageJ. (c) Western blot of HCT116 WT and PTEN null cells 32 h post transfection of ectopic MRE11A with or without
cycloheximide treatment for 8 and 24 h. The graph represents the quantiﬁcation of the MRE11A-Myc-Flag western blot signal by ImageJ.
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although there was a small increase in CHK1 activation compared
with control (Figure 4b). However, inhibition of AKT had little or no
effect on the activity of the downstream kinase mTORC1,
monitored using antibodies speciﬁc for its substrate p70S6K, or
on the activity of p70S6K itself, monitored using antibodies
speciﬁc for phosphorylated ribosomal protein S6 (Figure 4b). The
reason for this is currently unclear, as it is well-established that
AKT stimulates the activity of mTORC1 and p70S6K, although it
may be related to the existence of feedback loops within the AKT-
mTOR-p70S6K pathway. Regardless, the failure of AKT inhibition to
affect MRE11, RAD50 and CHK2 is likely due to its failure to inhibit
these key downstream effectors, mTORC1 and p70S6K.
Consistent with this interpretation, we observed that direct
inhibition of mTORC1 or p70S6K led to a pronounced increase in
MRE11 and RAD50 levels and signiﬁcant rescue of CHK1 and CHK2
activation after irradiation. As expected, inhibition of mTORC1
greatly inhibited both p70S6K and S6 phosphorylation, whereas
inhibition of p70S6K diminished S6 phosphorylation without
impairing mTORC1 activity (as judged by p70S6K phosphoryla-
tion). Taken together, these data implicate mTORC1 and p70S6K
activity in the control of MRE11 stability and checkpoint
proﬁciency. By the simplest model, mTORC1 exerts its effects on
MRE11 and RAD50 via p70S6K.
P70S6 kinase phosphorylates MRE11 to promote degradation
In silico analysis of MRE11 identiﬁed a threonine residue in
position 597 (T597) as a potential target of p70S6K phosphoryla-
tion, identical to the p70S6K consensus target site RXRXXT/S
(Figure 5a). To determine whether MRE11 could serve as a direct
substrate for p70S6K, we performed an in vitro kinase assay using
puriﬁed recombinant MRE11 and p70S6K proteins. We observed
that increasing amounts of p70S6K catalysed increased incorpora-
tion of 32P into a ﬁxed amount (200ng) of recombinant MRE11A as
observed by autoradiography and scintillation counting following
SDS–PAGE (Figures 5b and c). The extent of MRE11 substrate
phosphorylation was similar to that of p70S6K auto-phosphoryla-
tion, suggesting that the reaction was efﬁcient. To identify the
sites of in vitro phosphorylation of MRE11, we analysed the
phosphorylated protein by mass spectrometry. This analysis
conﬁrmed that T597 was a prominent site of phosphorylation,
Figure 4. MRE11 suppression is stimulated by mTORC1 and S6
kinase signalling. (a) Western blot analysis of HCT116 WT cells
transiently transfected with GAG-AKT and lysed at the indicated
time-points post transfection. Actin provides the loading control.
(b) Western blot analysis of HCT116 PTEN− /− cells treated for 72 h with
different inhibitors targeting various kinases within the AKT/mTOR/
S6K pathway. Seventy-two hours post treatment, cells were exposed
to IR and 1 h after were analysed. Actin provides the loading control.
Figure 5. S6K1 phosphorylates MRE11A in vitro. (a) Sequence
analysis of MRE11A reveals the presence of an S6K1 consensus
sequence. The analysis identiﬁed a site on T597. (b) SDS–PAGE
performed on recombinant Myc-MRE11A incubated with γ32P-ATP
and varying amounts of recombinant S6K1. The lower panel shows
Coomassie staining. (c) Scintillation counts of MRE11 bands cut from
the SDS–PAGE gel quantifying 32P incorporation into MRE11A.
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with lesser modiﬁcation of serine 619 (S619: Figures 6a and b).
Although we have not directly shown in this study that MRE11 is
phopshorylated on T597 in PTEN null cells, recently published data
have shown that the expression of Myr-AKT in cells induces Mre11
phosphorylation at T597.32 Altogether, these data are consistent
with the idea that in PTEN null cells with activated AKT, S6K1
phosphorylates MRE11 on T597 to direct its degradation.
Previous experiments showed that exogenous MRE11 was also
signiﬁcantly less stable in HCT116 PTEN− /− cells than wild-type
cells (Figure 3c). To determine whether phosphorylation of T597
might have a role in controlling MRE11 stability in this cellular
background, we generated mutants of MRE11 where T597 was
replaced by a non-phosphorylatable alanine residue (MRE11 T597A)
or by a phospho-mimetic aspartic acid residue (MRE11 T597D) by
site-directed mutagenesis. When transfected into HCT116 PTEN− /−
cells, MRE11 T597A accumulated to signiﬁcantly higher levels than
either MRE11 wild-type or MRE11 T597D (Figure 6c). Although
phosphorylation of T597 should be conﬁrmed in vivo, these results
are at least consistent with phosphorylation of T597 having a role in
promoting MRE11 degradation.
Figure 6. MRE11 degradation is mediated by S6K1 phosphorylation on T597. (a) Positive ion MS/MS spectra, of tryptic phosphopeptides (593–
604) and (617–625) of MRE11. The b and y ion series are indicated in blue and red, respectively. Dashed lines indicates b and y ion fragments
used to infer phosphorylation positions. (b) Summary of a. (c) Western blot of HCT116 PTEN null cells expressing ectopic MRE11A WT or
MRE11A T597A or MRE11A T597D 24 h post transfection. Actin provides the loading control.
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Activated AKT reinforces RAS-induced senescence via MRN
complex hypomorphism
Aside from ionising radiation, oncogene activation has also been
established as a powerful trigger of DNA damage and DNA
damage signalling. In primary human cells, expression of
oncogenic HRAS leads to an initial burst of cell proliferation
associated with a high level of DNA replication stress and DNA
damage, leading eventually to cellular senescence.33 The detri-
mental effect of activated AKT on MRE11 expression, and DNA
repair proﬁciency would modify cellular response to replication
Figure 7. Activated AKT pathway enhances RAS-induced senescence by inhibition of MRN complex. (a, c) Western blot analysis on IMR90 cells
12 days post infection with retroviruses expressing HRASG12V, Myr-AKT, HRASG12V/Myr-AKT or control virus (CTR). Actin provides a loading
control. (b, top) Immunoﬂuorescence images obtained following an alkaline comet assay with IMR90 cells 12 days post infection with CTR,
HRASG12V, Myr-AKT or HRASG12V and Myr-AKT retroviruses. (b, bottom) Total DNA damage (sum of single and double DNA breaks) was
measured as percentage of DNA migrated in the tail of the comet over the total signal from the head and tail. Error bars show S.D. for three
independent biological replicates. *** denotes Po0.001 as calculated by Student’s t-test. Data were quantiﬁed by using ImageJ OpenComet, and
it was derived from three independent biological replicates. (c) Western blot analysis on IMR90 cells 12 days post infection with retroviruses
expressing HRASG12V, Myr-AKT, HRASG12V/Myr-AKT or control virus (CTR). Actin provides a loading control. (d) Quantiﬁcation of SA β-
galactosidase-positive cells plotted as a percentage of total cells. The quantiﬁcation was performed on the average of 100 cells per sample.
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stress, consequently altering OIS. To investigate this possibility,
early passage IMR90 human ﬁbroblasts were transduced with
retroviruses encoding HRASG12V or activated, myristoylated AKT
(Myr-AKT) or both together.
Expression of exogenous HRASG12V and Myr-AKT in freshly
transduced IMR90 cultures was conﬁrmed by Western blotting.
The activity of Myr-AKT was evident through increased phosphor-
ylation of AKT on serine 473, of the direct AKT targets GSK3α/β,
and of the downstream mTORC1-p70S6K target, ribosomal protein
S6 (Figure 7a). As expected, HRASG12V expression caused
activation of DNA damage signalling, as judged by phosphorylation
CHK2 at T68 (Figure 7a). When expressed alone, Myr-AKT did not
induce DNA damage signalling as judged by CHK2 T68 phosphor-
ylation, although the basal level of CHK1 S345 phosphorylation was
suppressed (Figure 7a). As observed in HCT116 cells, expression of
active Myr-AKT in IMR90 cells resulted in reduced expression of
MRE11, RAD50 and NBS1 (Figure 7a). Moreover, when combined
with HRASG12V, active Myr-AKT inhibited Ras-induced activation of
CHK2 and suppressed the basal level of active CHK1, consistent
either with a defect in DNA damage signalling or mitigation of
HRASG12V-induced DNA damage.
To evaluate the impact of HRASG12V and Myr-AKT on genomic
integrity directly, an alkaline comet assay was performed. As
expected, cells transduced with HRASG12V showed a higher
level of DNA damage than control cultures, whereas cells expressing
Myr-AKT alone did not (Figure 7b). Importantly, cells expre-
ssing HRASG12V and Myr-AKT showed a signiﬁcant increase
(Po0.001) in comet tail length when compared with HRASG12V
only cells, ruling out the possibility that Myr-AKT suppresses DNA
damage signalling by mitigating HRASG12V-induced DNA damage
(Figure 7b).
We next asked whether expression of Myr-AKT modiﬁed
HRASG12V-induced cell senescence. IMR90 cell cultures were
transduced with HRASG12V, Myr-AKT or both together, and
analysed by western blotting for key senescence markers after
2 weeks in culture. Replicate dishes were stained for expression of
senescence-associated β-galactosidase (SA β-gal) activity 6 and
13 days after transduction. As shown in Figure 7c, this analysis
revealed that expression of HRASG12V-induced cell senescence, as
judged by an increase in the expression of the cyclin-dependent
kinase inhibitors p16 and p21, an increase in p53 serine 15 (S15)
phosphorylation, and a marked decrease in the expression of
cyclin A and phosphorylation of the retinoblastoma tumour
suppressor (pRb) at serines 807 and 811 (S807/ 811) compared
with control cultures. That these changes were associated with
senescence was conﬁrmed by a large increase in the proportion of
cells expressing SA β-gal (Figure 7d).
In marked contrast, expression of Myr-AKT alone did not
affect p16 and p21 expression, although cyclin A expression and
pRb S807/ 811 phosphorylation were diminished compared with
control cells. Consistent with this, SA β-gal expression was also
increased in Myr-AKT-expressing cultures, although to a lesser
extent than cells expressing HRASG12V alone (Figure 7d).
Strikingly, cells transduced with both HRASG12V and Myr-AKT
showed both upregulation of p16 and p21 and a more severe
suppression of cyclin A expression and pRb S807/811 phos-
phorylation than cells expressing either oncogene alone
(Figure 7c). Cultures expressing both HRASG12V and Myr-AKT
also contained a higher proportion of cells expressing SA β-gal
(Figure 7d).
The treatment of ER-RAS expressing cells with Mirin leads to
increased p16 and p21 levels when compared with untreated cells
(Supplementary Figure 2A). Mirin also causes a greater percentage
of cells to arrest in G1 phase (Supplementary Figure 2B). This
suggests that reduced MRE11 expression is likely to contribute to
the observed synergy between AKT and HRASG12V. We conclude,
based on these assays, that co-expression of Myr-AKT enhances
DNA damage induced by HRASG12V and reinforces the senes-
cence phenotype.
DISCUSSION
Here we have characterized a novel mechanism by which
inactivation of PTEN impairs cell cycle checkpoints and DNA
repair, and so promotes genome instability. Speciﬁcally, our
evidence supports a model whereby elevated AKT-mTORC1
signalling in PTEN-deﬁcient cells drives S6K-mediated phosphor-
ylation and hence destabilization of MRE11, a catalytic nuclease
whose activity is critical for DNA end resection and HR-mediated
repair.34,35 This occurs in at least two cell models, WT and PTEN
null HCT116 and DLD1 cells. At least in HCT116 cells, this is
associated with downregulation of the whole MRN complex,
impaired DNA end resection and suppression of error-free HR
repair. Interestingly, in DLD1 cells, loss of PTEN downregulates
abundance of catalytic subunit MRE11, but has a more modest
effect on MRE11’s non-catalytic partner proteins, RAD50 and NBS1.
The reason for the difference between MRE11 and NBS1 in the
two cell lines is not known, but could reﬂect genetic or epigenetic
variations, which in turn modulate expression of NBS1 and MRE11.
Regardless, as MRE11 is the catalytic exonuclease, its down-
regulation alone presumably impairs MRE11-mediated end resec-
tion. Of course, there are gaps in this study. For example, due to
the instability of the wild-type protein in PTEN-deﬁcient cells, we
have not shown whether ectopic expression of MRE11 rescues any
defects in PTEN-deﬁcient cells. Owing to the same reason, it has
proved difﬁcult to map phosphorylation sites on endogenous
MRE11 to conﬁrm its phosphorylation on T597. Despite such
relative weaknesses, our study provides a substantial body of data
in support of the proposed mechanism.
In addition to unleashing unrestrained activity of mitogenic
growth-promoting signalling pathways, inactivation of PTEN has
long been linked to genome instability in cancer. Here, we have
linked PTEN to preservation of genome stability though a novel
mechanism that depends on its control of the mitogenic kinase
signalling cascade, AKT-mTORC1-S6K impinging on the MRN
complex. This coupling of mitogenic signalling to genome
instability is intriguing. At ﬁrst, it seems counterintuitive that a
high level of mitogenic and nutrient signalling driving cell growth
and proliferation should be associated with decreased DNA repair
and increased genome instability. Yet, in fact, elevated mTOR
activity is associated with accumulation of diverse types of
molecular and cellular damage in many different biological
systems and species. Hence, increased mTOR activity is tightly
linked to decreased cellular and organismal longevity, conserved
across evolution.36 In this light, the link between high mTOR
activity and genome instability is not so surprising. Of course, our
ﬁndings in cancer cells and differentiated ﬁbroblasts might not
apply to all other cell types. Indeed, in murine hematopoietic stem
and progenitor cells, mTOR promotes the DDR and suppression of
DNA damage by upregulation of FANCD2.37 Nevertheless, our
study shows that at least colon cancer cells lacking PTEN are
consequently deﬁcient in DNA damage and repair. This might
confer an advantage for the tumour by making the genome more
plastic and evolvable. However, it may also have therapeutic
implications. Cancers deﬁcient in HR show promise as targets of
precision medicine approaches that exploit this weakness in the
cancer’s defence. Our study underscores previous studies that
have linked loss of PTEN to defective HR repair.38
In this study, we also showed that inactivation of PTEN function
recapitulated through activation of AKT cooperates with an
activated oncogene to drive robust OIS. This ﬁnding is seemingly
at odds with a previous study of Peeper and coworkers39 showing
that inactivation of PTEN promotes bypass of BRAFV600E-induced
senescence. On the other hand, the observations reported in this
MS are consistent with others previously published from our lab.40
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In this prior study, we showed that although inactivation of PTEN
and activation of AKT bypassed some features of OIS, these
interventions failed to overcome oncogene-induced proliferation
arrest, an observation recapitulated here. DNA damage and DNA
damage signalling are major drivers of cellular senescence-
associated proliferation arrest.33 Hence, the increased damaged
DNA load and DNA damage signalling in cells lacking PTEN is
expected to acutely promote senescence-associated proliferation
arrest, as we observed here. However, in a mouse model of
pancreatic cancer, we also found that inactivation of PTEN
cooperates with activated RASG12D to escape senescence and
promote pancreatic cancer, in an mTOR dependent manner. As we
noted previously,40 in this in vivo model, inactivation of PTEN might
cooperate with RASG12D to escape senescence and promote
pancreatic cancer via cooperation with additional acquired and
selected mutations. This current study supports the notion that
inactivation of PTEN can, possibly by destabilization of MRE11 and
suppression of HR, promote the accumulation of such additional
cooperating genetic rearrangements and mutations.
In sum, this study sheds light on the molecular mechanism by
which inactivation of PTEN promotes tumorigenesis and may
confer sensitivity to a speciﬁc class of anti-cancer therapeutic.
MATERIALS AND METHODS
Cell culture, transfections and chemical inhibitors
HCT116 WT, HCT116 PTEN− /−, DLD1 and DLD1 PTEN− /− (gift from Todd
Waldman), Phoenix-AMPHO embryonic kidney cells (SD-3443, ATCC)(used
for the generation of helper-free ecotropic and amphotropic retroviruses)
cells were grown in DMEM supplemented with 10% FBS, 2 mM L-glutamine,
50 U/ml penicillin and 50 μg/ml streptomycin at 37 °C. Human foetal lung
primary ﬁbroblasts IMR90 were obtained from Coriell Cell Repositories.
They were cultured in DMEM supplemented with 20% FBS, 2 mM L-glutamine,
50 U/ml penicillin and 50 μg/ml streptomycin at 37 °C and 3% O2.
Cells were irradiated using the Xstrahl RS225 unit
HCT116 WT cells were pre-treated for 40 mins with 50 and 100 μM of Mirin
(M9948 Sigma, Schnelldorf, Germany) before experimental treatment as
appropriate. HCT116 PTEN− /− were pre-treated for 72 h with 2 μM of AKT1/2
inhibitor (A6730 Sigma), 500 nM of Everolimus (07741 Sigma) and 10 μM of
S6K1 inhibitor (PF4708671 Tocris Bioscence, Abingdon, UK) before experi-
mental treatment as appropriate.
MRE11A and non-targeting siRNA (L009271, D001810 Dharmacon,
Lafayette, CO, USA) were transfected into HCT116 WT cells using
Lipofectamine 2000 (Invitrogen, Thermo Fisher Scientiﬁc, Carlsbad, CA,
USA). All siRNA transfection were performed with a ﬁnal concentration of
200 nM for 48 h.
Immunocytochemistry
Coverslips were pre-treated with extraction buffer (25 mM HEPES pH 7.4,
50 mM NaCl, 1 mM EDTA, 3 mM MgCl2, 300 mM sucrose, 0.5% Triton-X100) as
described previously.41 The cells were ﬁxed with 4% of paraformaldehyde
for 15 min at room temperature, permeabilize with 0.5% Triton-X and
incubated with blocking buffer (3% of BSA in PBS) for 30 min. The cells
were then incubated with 1:200 dilution of primary antibody overnight and
1:200 secondary antibody for 1 h. The cells were then stained with DAPI,
and images acquired with a × 60 oil immersion lens on a NikonA1R laser
scanning confocal microscope (Tokyo, Japan). The number of foci were
counted manually by using ImageJ software (National Institute of Health,
Bethesda, MD, USA).
Flow cytometry
Cells were ﬁxed in ice-cold 70% ethanol in PBS and kept at 4 °C for 30 min.
For the measurement of mitotic index cells were stained with anti-
phospho histone H3 (pS10 H3) and propidium iodide, and analysed at
FACScan ﬂow cytometer as described previously.42 For cell proliferation
analysis cells were labelled with 25 μM BrdU, and then ﬁxed and stained
using anti-BrdU antibody as described previously.43
The NHEJ and HR reporter vectors were obtained from Vera Gorbunova’s
lab.31 In the extrachromosomal assay, 0.5 μg of linearized NHEJ or 2 μg of
HR reporter construct were co-trasfected with 0.1 μg of pDs-Red2-N1 as
transfection control, and analysed after 24 h by FACScan (Becton Dickinson
FACScan Analyser, Walpole, MA, USA). Cells transfected with 1 μg of GFP-
expressing plasmid, 1 μg of pDs-Red2-N1 and 1 μg of a control plasmid
were used as calibration controls for the FACS prior to the analysis. The
efﬁciency of DNA DSB repair was calculated as the ratio of GFP+ to DsRed
+ cells.
Gene expression analysis
SuperScript III reverse transcriptase (Invitrogen, Thermo Fisher Scientiﬁc)
was used as per manufacturers instructions with 0.4 μg of RNA and
Hexanucleotide Mix (Roche, Sigma, Schnelldorf, Germany). RT–PCR was
performed using the C1000TM Thermal Cycler (Bio-Rad) using PerfeCTaTM
SYBR Green FastMixTM (Quanta Bioscience, Beverly, MA, USA) and 0.25 μM
of primers in Supplementary Table 1. The average of the ΔΔC(t) of
duplicate samples was calculated using actin as a lading control. Overall
average and s.d. values were calculated from three independent
experiments.
Recombinant protein puriﬁcation
pGEX4T1 purchased from Novagen (Madison, WI, USA) and MRE11A cloned
using In-Fusion HD (Clontech, Mountain View, CA, USA). Recombinant GST-
MRE11A was expressed in BL21 E. coli plus RIL strain from pET156P vector.
Bacteria were cultured in Terriﬁc Broth at 37 °C to an A600 of 1.2 and
protein expression was induced with 0.4 mM IPTG overnight at 16 °C. Cells
were harvested by centrifugation, washed in ice-cold PBS and lysed in
50 mM Tris-Cl pH 7.5, 250 mM NaCl, 0.5 mM EDTA, 0.5 mM EGTA, 0.5% Triton-
X100, 1 mm DTT, 20 μg/Ml leupeptin, 1 mM pefabloc, 0.5 mM TCEP by
sonication. GST-MRE11A was puriﬁed using glutathione afﬁnity resin,
quantiﬁed by A280 with a Nanodrop and analysed by SDS–PAGE prior
to use.
Western blotting
Whole-cell lysates were resolved by SDS–PAGE, immobilized to PVDF, and
subjected to western blotting as previously described.44 Antibodies used
are listed in Supplementary Table 2.
Kinase assay
A range of 13–210 ng of kinase and the 200 ng of substrate were incubated
at 30 °C for 30 min along with 2 mM DTT, 20 mM Tris, 1 mM EGTA, 1 mM
MgCl2 and 1 μl of 2 μCi/μl [γ-32P]. 4 ×NuPAGELDS (Invitrogen, Thermo
Fisher Scientiﬁc) sample buffer was added to the samples, then boiled at
95 °C for 5 min and resolved on a SDS–PAGE gel, which were coomassie
stained. Signal was visualized by autoradiography. The proteins bands of
interest were then excised and 32P incorporation was quantiﬁed by
Cerenkov counting in a scintillation counter.
Alkaline comet assay analysis
Alkaline comet assay was perfomed using the Comet assay kit (Trevigen,
Gaithersburg, MD, USA) and performed as described by manufacturer.
DNA was stained using SYBR Gold (Invitrogen, Thermo Fisher Scientiﬁc)
and visualised by ﬂuorescent microscopy. Images were analysed by using
OpenComet plug-in in ImageJ, and 100 cells were counted for each
treatment.
β-galactosidase staining
Cells were seeded onto glass coverslips prior the onset of senescence. SA
β-gal staining was performed as previously described45 and visualised
using conventional bright ﬁeld microscopy.
Proteolytic digestion of proteins ‘in gel’
The region containing MRE11A was excised from gel and digested
according to a previously described procedure.46
Mass spectrometry
The tryptic digest obtained was separated by nanoscale C18 reverse-phase
liquid chromatography using an EASY-nLC II coupled to a Linear Trap
Quadrupole-Orbitrap Velos Thermo Fisher Scientiﬁc, Carlsbad, CA, USA.
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The mass spectrometer was used in data-dependent mode, the top ten
most intense ions from each survey scan were fragmented in the linear ion
trap using collision-induced dissociation enabling the ‘multistage activa-
tion’ option.
Data analysis
Raw data obtained were processed with Raw2MSN,47 and analysed using
Mascot (Matrix Science, version 2.4.1, Boston, MA, USA), querying both:
Homo sapiens UniProt database (release 2014_01, UniProt consortium,
Cambridge, UK, restricted to, 20273 entries)48 and an in-house database
containing common proteomic contaminants and the sequence of MRE11
construct.
Cysteine carbamidomethylation was speciﬁed as ﬁxed modiﬁcation, and
variable modiﬁcations were allowed for acetylation of protein N terminus,
oxidation of methionine, and phosphorylation of serine and threonine and
tyrosine.
Scaffold (version 4.3.2, Proteome Software, Portland, OR, USA) was used to
validate MS/MS-based peptide and protein identiﬁcations, and peptide false
discovery rate was 0.9%.49
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